Clinigen Group PLC (CLIN) Receives Buy Rating from N+1 Singer

N+1 Singer restated their buy rating on shares of Clinigen Group PLC (LON:CLIN) in a research note released on Wednesday morning. They currently have a GBX 800 ($10.44) price target on the stock.

A number of other research analysts also recently weighed in on CLIN. Peel Hunt reissued a buy rating and issued a GBX 1,000 ($13.05) price target on shares of Clinigen Group PLC in a research note on Thursday, June 9th. Numis Securities Ltd reaffirmed a buy rating on shares of Clinigen Group PLC in a research note on Friday, June 24th. Finally, Stifel Nicolaus reaffirmed a buy rating and set a GBX 800 ($10.44) price objective on shares of Clinigen Group PLC in a research note on Wednesday, July 20th. Five research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and a consensus target price of GBX 856.60 ($11.18).

Shares of Clinigen Group PLC (LON:CLIN) traded down 2.48% during mid-day trading on Wednesday, hitting GBX 687.50. The company’s stock had a trading volume of 215,750 shares. Clinigen Group PLC has a 1-year low of GBX 492.75 and a 1-year high of GBX 739.50. The stock’s market cap is GBX 767.24 million. The company has a 50-day moving average price of GBX 653.09 and a 200-day moving average price of GBX 597.88.

The firm also recently disclosed a dividend, which will be paid on Friday, November 25th. Investors of record on Thursday, November 3rd will be paid a dividend of GBX 2.70 ($0.04) per share. This represents a yield of 0.38%. The ex-dividend date of this dividend is Thursday, November 3rd. This is an increase from Clinigen Group PLC’s previous dividend of $1.30.

Clinigen Group PLC Company Profile

Clinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP).

Receive News & Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.